| Literature DB >> 26358256 |
Juan Chen1,2,3, Lin Wu4, Ying Wang4, Jiye Yin1,2,3, Xiangping Li1,2, Zhan Wang5, Huihua Li6, Ting Zou1,2, Chenyue Qian1,2, Chuntian Li7, Wei Zhang1,2,3, Honghao Zhou1,2,3, Zhaoqian Liu8,9,10.
Abstract
Lung cancer is the first leading cause of cancer deaths. Chemotherapy toxicity is one of factors that limited the efficacy of platinum-based chemotherapy in lung cancer patients. Transporters and DNA repair genes play critical roles in occurrence of platinum-based chemotherapy toxicity. To investigate the relationships between transporter and DNA repair gene polymorphisms and platinum-based chemotherapy toxicity in lung cancer patients, we selected 60 polymorphisms in 14 transporters and DNA repair genes. The polymorphisms were genotyped in 317 lung cancer patients by Sequenom MassARRAY. Logistic regression was performed to estimate the association of toxicity outcome with the polymorphisms by PLINK. Our results showed that polymorphisms of SLC2A1 (rs3738514, rs4658, rs841844) were significantly related to overall toxicity. XRCC5 (rs1051685, rs6941) and AQP2 (10875989, rs3759125) polymorphisms were associated with hematologic toxicity. AQP2 polymorphisms (rs461872, rs7305534) were correlated with gastrointestinal toxicity. In conclusion, genotypes of these genes may be used to predict the platinum-based chemotherapy toxicity in lung cancer patients.Entities:
Keywords: Chemotherapy toxicity; DNA repair gene; Genetic polymorphism; Lung cancer; Platinum; Transporter
Mesh：
Substances：
Year: 2015 PMID： 26358256 DOI： 10.1007/s13277-015-4048-0
Source DB: PubMed Journal: Tumour Biol ISSN： 1010-4283